Â
Orlistat Quick Details
Â
Product Name: | Orlistat |
CAS: | 96829-58-2 |
MF: | C29H53NO5 |
MW: | 495.73 |
Product Categories: | Pharmaceutical Raw Materials;Miscellaneous Biochemicals;API;Antiobesity Agent;Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals;Amino Acids & Derivatives;Heterocycles;ACTOS;Other APIs;Lipid-lowering medicine reducing weight |
Mol File: | 96829-58-2.mol |
Orlistat Dosage and Administration
Adults
The recommended dose of orlistat is one 120 mg capsule taken with water immediately before, during or up to one hour after each main meal. If a meal is missed or contains no fat, the dose of orlistat should be omitted.
The patient should be on a nutritionally balanced, mildly hypocaloric diet that contains approximately 30 % of calories from fat. It is recommended that the diet should be rich in fruit and vegetables. The daily intake of fat, carbohydrate and protein should be distributed over three main meals.
Doses of orlistat above 120 mg three times daily have not been shown to provide additional benefit.
The effect of orlistat results in an increase in faecal fat as early as 24 to 48 hours after dosing. Upon discontinuation of therapy, faecal fat content usually returns to pre-treatment levels, within 48 to 72 hours.
Special populations
The effect of orlistat in patients with hepatic and/or renal impairment, children and elderly patients has not been studied.
There is no relevant indication for use of Venical in children.
Orlistat Usage
2. antidiabetic
3. Orlistat is an antiobesity agent. Orlistat is an pancreatic lipase inhibitor.
4. Tetrahydrolipstatin (orlistat) is a semi-synthetic derivative of lipstatin, a metabolite isolated from Streptomyces toxytricini. Tetrahydrolipstatin acts as a potent, irreversible inhibitor of pancreatic lipase. In vivo, it blocks the absorption of triglycerides while allowing fatty acid absorption. Tetrahydrolipstatin is widely used for the treatment of obesity.
5. Orlistat is used for the treatment of obesity. The amount of weight loss achieved with orlistat varies. In one-year clinical trials, between 35.5% and 54.8% of subjects achieved a 5% or greater decrease in body mass, although not all of this mass was necessarily fat. Between 16.4% and 24.8% achieved at least a 10% decrease in body fat. After orlistat was stopped, a significant number of subjects regained weight-up to 35% of the weight they had lost.
6. The incidence of type 2 diabetes in an obese population over four years is decreased with orlistat (6.2%) compared to placebo (9.0%). Long-term use of orlistat also leads to a modest reduction in blood pressure (mean reductions of 2.5 and 1.9 mmHg in systolic and diastolic blood pressure respectively).
Orlistat Applications
The effectiveness of orlistat in promoting weight loss is definite, though modest. Pooled data from clinical trials suggest that people given orlistat in addition to lifestyle modifications, such as diet and exercise, lose about 2-3 kilograms more than those not taking the drug over the course of a year.Orlistat also modestly reduces blood pressure, and appears to prevent the onset of type 2 diabetes, whether due to weight loss itself or to other effects; in a large randomized controlled trial, orlistat was found to reduce the incidence of diabetes by nearly 40% in obese people.
Orlistat is notorious for its gastrointestinal side effects (sometimes referred to as treatment effects), which can include steatorrhea (oily, loose stools). In the United States and the European Union, orlistat is available for sale without a prescription.  Generic formulations of orlistat are available in some countries.
Orlistat Image




Peptides product listÂ
Â
Peptides | ||
 | Name | Specification |
T-A001 | MGF | 2mg/vial |
T-A002 | PEG MGF | 2mg/vial |
T-A003 | CJC-1295 with DAC | 2mg/vial |
T-A004 | CJC-1295 without DAC | 2mg/vial |
T-A005 | PT-141 | 10mg/vial |
T-A006 | MT-1(Melanotan) | 10mg/vial |
T-A007 | MT-2 | 10mg/vial |
T-A008 | GHRP-2 | 5mg/vial |
T-A008 | GHRP-2Â | 10mg/vial |
T-A009 | GHRP-6 | 5mg/vial |
T-A009 | GHRP-6 | 10mg/vial |
T-A010 | Ipamorelin | 2mg/vial |
T-A011 | Hexarelin | 2mg/vial |
T-A012 | Sermorelin | 2mg/vial |
T-A013 | Oxytocin | 2mg/vial |
T-A014 | TB500 | 2mg/vial |
T-A015 | pentadecapeptide BPC 157 | 2mg/vial |
T-A016 | Fragment 176-191 | 2mg/vial |
T-A017 | Triptorelin | 2mg/vial |
T-A018 | Tesamorelin | 2mg/vial |
T-A020 | Gonadorelin | 2mg/vial |
T-A020 | Gonadorelin | 10mg/vial |
T-A021 | DSIPÂ | 2mg/vial |
T-A022 | Selank | 5mg/vial |
T-A023 | Follistatin 344Â | 1mg/vial |
T-A024 | GDF-8 | 1mg/vial |
T-A025 | ACE 031 | 1mg/vial |
T-A026 | FOLLISTATIN 314 | 1mg/vial |
If you have any questions, you can contact me.
Nicole
Tel:+86 18872220801
Â
Orlistat Quick Details
Â
Product Name: | Orlistat |
CAS: | 96829-58-2 |
MF: | C29H53NO5 |
MW: | 495.73 |
Product Categories: | Pharmaceutical Raw Materials;Miscellaneous Biochemicals;API;Antiobesity Agent;Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals;Amino Acids & Derivatives;Heterocycles;ACTOS;Other APIs;Lipid-lowering medicine reducing weight |
Mol File: | 96829-58-2.mol |
Orlistat Dosage and Administration
Adults
The recommended dose of orlistat is one 120 mg capsule taken with water immediately before, during or up to one hour after each main meal. If a meal is missed or contains no fat, the dose of orlistat should be omitted.
The patient should be on a nutritionally balanced, mildly hypocaloric diet that contains approximately 30 % of calories from fat. It is recommended that the diet should be rich in fruit and vegetables. The daily intake of fat, carbohydrate and protein should be distributed over three main meals.
Doses of orlistat above 120 mg three times daily have not been shown to provide additional benefit.
The effect of orlistat results in an increase in faecal fat as early as 24 to 48 hours after dosing. Upon discontinuation of therapy, faecal fat content usually returns to pre-treatment levels, within 48 to 72 hours.
Special populations
The effect of orlistat in patients with hepatic and/or renal impairment, children and elderly patients has not been studied.
There is no relevant indication for use of Venical in children.
Orlistat Usage
2. antidiabetic
3. Orlistat is an antiobesity agent. Orlistat is an pancreatic lipase inhibitor.
4. Tetrahydrolipstatin (orlistat) is a semi-synthetic derivative of lipstatin, a metabolite isolated from Streptomyces toxytricini. Tetrahydrolipstatin acts as a potent, irreversible inhibitor of pancreatic lipase. In vivo, it blocks the absorption of triglycerides while allowing fatty acid absorption. Tetrahydrolipstatin is widely used for the treatment of obesity.
5. Orlistat is used for the treatment of obesity. The amount of weight loss achieved with orlistat varies. In one-year clinical trials, between 35.5% and 54.8% of subjects achieved a 5% or greater decrease in body mass, although not all of this mass was necessarily fat. Between 16.4% and 24.8% achieved at least a 10% decrease in body fat. After orlistat was stopped, a significant number of subjects regained weight-up to 35% of the weight they had lost.
6. The incidence of type 2 diabetes in an obese population over four years is decreased with orlistat (6.2%) compared to placebo (9.0%). Long-term use of orlistat also leads to a modest reduction in blood pressure (mean reductions of 2.5 and 1.9 mmHg in systolic and diastolic blood pressure respectively).
Orlistat Applications
The effectiveness of orlistat in promoting weight loss is definite, though modest. Pooled data from clinical trials suggest that people given orlistat in addition to lifestyle modifications, such as diet and exercise, lose about 2-3 kilograms more than those not taking the drug over the course of a year.Orlistat also modestly reduces blood pressure, and appears to prevent the onset of type 2 diabetes, whether due to weight loss itself or to other effects; in a large randomized controlled trial, orlistat was found to reduce the incidence of diabetes by nearly 40% in obese people.
Orlistat is notorious for its gastrointestinal side effects (sometimes referred to as treatment effects), which can include steatorrhea (oily, loose stools). In the United States and the European Union, orlistat is available for sale without a prescription.  Generic formulations of orlistat are available in some countries.
Orlistat Image




Peptides product listÂ
Â
Peptides | ||
 | Name | Specification |
T-A001 | MGF | 2mg/vial |
T-A002 | PEG MGF | 2mg/vial |
T-A003 | CJC-1295 with DAC | 2mg/vial |
T-A004 | CJC-1295 without DAC | 2mg/vial |
T-A005 | PT-141 | 10mg/vial |
T-A006 | MT-1(Melanotan) | 10mg/vial |
T-A007 | MT-2 | 10mg/vial |
T-A008 | GHRP-2 | 5mg/vial |
T-A008 | GHRP-2Â | 10mg/vial |
T-A009 | GHRP-6 | 5mg/vial |
T-A009 | GHRP-6 | 10mg/vial |
T-A010 | Ipamorelin | 2mg/vial |
T-A011 | Hexarelin | 2mg/vial |
T-A012 | Sermorelin | 2mg/vial |
T-A013 | Oxytocin | 2mg/vial |
T-A014 | TB500 | 2mg/vial |
T-A015 | pentadecapeptide BPC 157 | 2mg/vial |
T-A016 | Fragment 176-191 | 2mg/vial |
T-A017 | Triptorelin | 2mg/vial |
T-A018 | Tesamorelin | 2mg/vial |
T-A020 | Gonadorelin | 2mg/vial |
T-A020 | Gonadorelin | 10mg/vial |
T-A021 | DSIPÂ | 2mg/vial |
T-A022 | Selank | 5mg/vial |
T-A023 | Follistatin 344Â | 1mg/vial |
T-A024 | GDF-8 | 1mg/vial |
T-A025 | ACE 031 | 1mg/vial |
T-A026 | FOLLISTATIN 314 | 1mg/vial |
If you have any questions, you can contact me.
Nicole
Tel:+86 18872220801
Sinoscope Set,Sinoscope Full Set,Sinoscope For Ent,Ent Nasal Endoscope
ZHEJIANG SHENDASIAO MEDICAL INSTRUMENT CO.,LTD. , https://www.shendasiaomed.com